{"name":"Altavant Sciences GmbH","slug":"altavant-sciences-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Radio-labeled rodatristat ethyl 600 mg","genericName":"Radio-labeled rodatristat ethyl 600 mg","slug":"radio-labeled-rodatristat-ethyl-600-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Radio-labeled rodatristat ethyl 600 mg","genericName":"Radio-labeled rodatristat ethyl 600 mg","slug":"radio-labeled-rodatristat-ethyl-600-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOVnhicnpLNlV1RWM3M2RMTEs5MmstY0xQcVM0X0NwQ3FFSnRNdC03WlZ3a0NXVFpFV2NkanhScHlJQXFfbTgtZDE3VGxRRk5mZ054Q21WVlJPMGxuVE1tRVdPVDlSX3lfdWdFX1d2M2VuQ2ZMOEVVOW9hQ2VMT1RBNW1URnlJdnlvMFRsYW42NEI?oc=5","date":"2025-08-05","type":"pipeline","source":"openPR.com","summary":"Bronchiolitis Obliterans Syndrome Therapeutics 2025 | Immunosuppressives, Monoclonal Antibodies & Digital Health - openPR.com","headline":"Bronchiolitis Obliterans Syndrome Therapeutics 2025 | Immunosuppressives, Monoclonal Antibodies & Digital Health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQeHhISHVyb2Z5d2h0aGoyZW4takJhLTlQaDlYbFFlaTRvMnBrN3h6cEttemhWelM0SzRkRFlzVlkzTkdET1dqb2xZcVdjZ0pKWGZIVnd0QnBDRHJjN0J3WXZmaWRpU0g4VndCYk9zSE94dF80VWNWX01MYXpJci02SFozdHlOdlR2TkM0ckNpdjBzVHE5U2hVUzc0U0dMODBXZkNYY08xOFh1OE53eWRRYi03cUIwQlh3d0JvTU41djhNMm9Mc3hBelZldmRETjlQd3ptNmlkY2RuQm9zR1F4WlMzeVQyUnhxeDdBSUNSbjRJX1NLVjI0ZEs0bmY3dWh4dDd1TFZKbjlpNTlIeXdqdm9PWG1mS3hEMTNTTmRjZw?oc=5","date":"2025-01-20","type":"trial","source":"GlobeNewswire","summary":"Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire","headline":"Advancements in Ocular Hypertension Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-07-19","type":"pipeline","source":"PR Newswire","summary":"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer B","headline":"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Ba","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOMXRYc0dZdTRMMkZfZ0tIdm14NHU1ZzdZMG1GdVZhVEZoa29qR09FTEN6Y3Y4dmh0MGF2R2xkaTZhQ0Z2Nkp5X0M0em5BTUlMNEkzaVNWTmxkNk0zYl8tQ0dXSXRRNndJbFEzcTkyNGEyUzNZVEN0SGJlT1ZWb0hTeU1QcFRRZmtaYWQ2dGNjN01ERDl5bDEzR00wQ2xPUXhlU0JqZTFRdlo3TExzb2FoMGwzZnQ?oc=5","date":"2022-12-08","type":"deal","source":"PMLiVE","summary":"Enzyvant and Altavant announce merger to accelerate rare disease therapies - PMLiVE","headline":"Enzyvant and Altavant announce merger to accelerate rare disease therapies","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}